Sophie Poznanski, PhD, shared insights with Lung Cancers Today from our presentation of preclinical data on AVC-S-101
Read More
BioWorld News: Avidicure boosting immune activation with $50M seed round to advance novel antibody formats
Read More
Avidicure CEO Arthur Lahr to present at annual BIO International Convention 2025
Read More
Avidicure to Present Preclinical Data from Lead Program at ASCO
Read More
Avidicure Launches with $50 Million in Seed Financing
Read More
Avidity engineered multispecific antibodies that are highly efficacious in immune cell stimulation
Read More
